P024 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
Published: Sep 1, 2021
Abstract
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Surgical resection and local ablation are potentially curative options for patients with HCC; however, tumor recurrence is not uncommon. The lack of a standard-of-care adjuvant therapy for HCC highlights an urgent therapeutic need to prevent disease recurrence and improve overall survival. Pembrolizumab, a PD-1 inhibitor, has shown...Paper Details
Title
P024 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
Published Date
Sep 1, 2021
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History